Aquatic concentration and risk assessment of pharmaceutically active compounds in the environment
Carolina Rodrigues Dos Santos1, Gemima Santos Arcanjo2, Lucilaine Valéria de Souza Santos3
1Department of Sanitary and Environmental Engineering, Universidade Federal de Minas Gerais, 30270-901, Belo Horizonte, MG, Brazil.
Abstract:
Pharmaceutically active compounds are increasingly detected in raw and treated wastewater, surface water, and drinking water worldwide. These compounds can cause adverse effects to the ecosystem even at low concentrations and, to assess these impacts, toxicity tests are essential. However, the toxicity data are scarce for many PhACs, and when available, they are dispersed in the literature. The values of pharmaceuticals concentration in the environment and toxicity data are essential for measuring their environmental and human health risks. Thus this review verified the concentrations of pharmaceuticals in the aquatic environment and the toxicity related to them. The risk assessment was also carried out. Diclofenac, naproxen, erythromycin, roxithromycin, and 17β-estradiol presented a high environment risk and 17α-ethinylestradiol presented a high human health risk. This shows the potential of these pharmaceuticals to cause adverse effects to the ecosystem and humans and establishes the necessity of their removal through advanced technologies.
More Related Videos
16:02Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
05:47In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
Related Concept Videos
Drug Concentrations: Measurements
Plasma...
Drug Concentration Versus Time Correlation
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Drug Biotransformation: Overview
Drug Distribution: Tissue Binding
For...
